Recommendations for cancer related fatigue in post-treatment survivorship care: a cross-sectional analysis of guidelines

SPECIAL REPORT

Breast Cancer

Managing Side Effects in Breast Cancer Treatment

Breast Cancer

Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis

Breast Cancer Res Treat

Blum M, Koch SM, Mousavi M, Vorburger D, Müller A, Zimmermann MEN, Oehler C, Zwahlen DR

doi: 10.1007/s10549-025-07890-5

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Lung, Respiratory and Thoracic Cancer

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

Lung Cancer

Wang Y, Zhang L, Zhan J, Wen L, Zhao X, Sun H, Chen X, Zhang Y, Chen G, Zhao Y, Huang Y, Fang W, Zhang L, Sun D, Yang Y

doi: 10.1016/j.lungcan.2026.108914

Head and Neck Cancer

Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial

Eur J Cancer

Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Richardson K, Mlynarek A, Johnson-Obaseki S, Gaudet M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Kwan K, Theurer J, Bahig H, Christopoulos A, Mendez LC, Sathya J, Hammond JA, Read N, Venkatesan V, Fung K, Nichols AC

doi: 10.1016/j.ejca.2025.115343

Multiple Myeloma (MM)

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline

J Clin Oncol

Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, Wildes TM, Bal S, Bhella S, Chmielewski C, Costello C, Dabney R, Hartley-Brown M, Langerak A, Lipe B, Martin T, McCurdy A, Mian H, Riva E, Seth R, Subramanian L, Mikhael J

doi: 10.1200/JCO-25-02587

Gastrointestinal Cancer

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306

Eur J Cancer

Holch JW, Ohnmacht AJ, Stintzing S, Heinrich K, Weiss L, Probst V, Stahler A, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Link H, Höffkes HG, Moehler M, Modest DP, Menden MP, Heinemann V

doi: 10.1016/j.ejca.2025.115388

COVID-19

Comparative inpatient care of cancer vs. non-cancer patients in Switzerland during the national COVID-19 lockdown: a nationwide interrupted time series analysis

BMC Cancer

Brunner L, Nicolet A, Peytremann-Bridevaux I, Marti J, Bulliard JL, Righi L, Britschgi C, Wicki A, Bienvenu C, Ganz-Blaettler U, Eicher M, Michielin O, Moschetti K, Le Pogam MA

doi: 10.1186/s12885-025-13818-5

Further Publications

Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled Trial

Semin Oncol Nurs

Lopes AMDS, Giacomini S, Ulahannan A, Darnac C, Bugeia S, Gutknecht G, Colomer-Lahiguera S, Spurrier-Bernard G, Latifyan S, Addeo A, Michielin O, Eicher M

doi: 10.1016/j.soncn.2025.151903

Related content

Managing Side Effects in Breast Cancer Treatment

Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306

Comparative inpatient care of cancer vs. non-cancer patients in Switzerland during the national COVID-19 lockdown: a nationwide interrupted time series analysis

Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled Trial